LOW TESTOSTERONE IN THE GLP-1 ERA Reframing male hormonal health, metabolic hypogonadism, testosterone replacement therapy and the emerging nutraceutical opportunity

Low testosterone is an important determinant of male health, but the consumer shorthand “low T” often collapses several distinct clinical situations into a single narrative. True hypogonadism requires compatible symptoms or signs together with repeatedly low testosterone concentrations; fatigue, low libido or reduced vitality alone are not diagnostic. A particularly important distinction is between organic hypogonadism and potentially reversible functional hypogonadism associated with obesity, insulin resistance, type 2 diabetes, sleep disorders, medications and chronic disease. [1,2] The rapid adoption of GLP-1 receptor agonists and related incretin therapies changes this landscape. Weight loss and metabolic improvement can partially reverse obesity-associated suppression of the hypothalamic-pituitary-gonadal axis. Recent clinical studies and meta-analyses increasingly report improvements in total, free or bioavailable testosterone among metabolically compromised men receiving GLP-1-based therapy, although a direct gonadal effect remains unproven. [8-13] At the same time, pharmacologically induced weight reduction can include loss of lean tissue, creating a second opportunity around muscle preservation, protein adequacy, resistance exercise and micronutrient sufficiency. [14,15] This convergence supports a more sophisticated category: male metabolic-androgen health. The commercial proposition should complement, not mimic, medically indicated TRT.